FSCN1 and type 2 diabetes mellitus: Circulating FSCN1 levels in blood samples collected before surgery of ACC patients (stage I/II and stage III/IV) were significantly higher than those in the serum samples of the two cohorts of non-tumoral control subjects (fold increase, FI: 5.5 ± 0.5, P<0.0001 and 8.0 ± 0.5, P<0.0001 for stage I/II and stage III/IV group vs healthy controls, respectively; FI: 2.4 ± 0.4, P<0.01 and 3.5 ± 0.2, P<0.001 for stage I/II and stage III/IV group vs obese/T2D subjects, respectively; Figure 1A).